Impact of LEAM and CBV conditioning on gastrointestinal toxicity at early periods following hematopoietic cell transplantation: A retrospective study
Gastrointestinal toxicity after LEAM and CBV
DOI:
https://doi.org/10.46765/2675-374X.2021v2n2p51Keywords:
Lymphoma. LEAM. CBV. Oral mucositis. Autologous hematopoietic cell transplantation.Abstract
Objectives: To compare the severity of oral mucositis and the frequency of gastrointestinal mucositis, and to observe if there is impact of these adverse effects on overall survival (OS), in patients who underwent CBV (carmustine, BCNU, and VP-16) and LEAM (lomustine, etoposide, Ara-C, and melphalan) conditioning for autologous hematopoietic cell transplantation (aHCT). Method: We collected retrospective data from medical records (n = 120) of transplantation and mucositis in the digestive tract of Hodgkin’s and non-Hodgkin’s lymphoma patients. Results: The frequency of OM grade 1 was higher in LEAM (36.76%) than in CBV (19.72%, p=0.038). There were no significant differences between the frequency of gastrointestinal mucositis in the two regimens (CBV - 52.11% and LEAM - 63.27%, p=0.305). CBV regimen exhibited lower 1-year overall survival (OS) than did LEAM (p=0.003). Oral mucositis grade ≥2 was associated with reduced OS in the CBV group (p=0.013). CBV regimen (HR=2.98, p 0.005) and oral mucositis grade ≥2 (HR=2.17, p=0.013) interfered negatively on the OS rate. Conclusion: Oral mucositis was more severe in CBV than in LEAM, decreasing the OS rate. Further studies with comprehensive follow-up and toxicity analyses must be undertaken to clarify the safety of LEAM conditioning in the digestive tract.
Downloads
Published
How to Cite
Issue
Section
License
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.